Human infection with avian influenza A(H7N9) virus - 5th update, 27 January 2017
Fifth update of the risk assessment on human infection with avian influenza A(H7N9) virus, summarising the epidemiological and virological information on the disease in China and Canada, and assessing the risk to public health in the EU/EEA.
Human infection with a novel avian influenza virus, A(H7N9), China - 2nd update, 8 May 2013
This second update to ECDC's initial risk assessment concludes that the risk of the disease spreading to Europe via humans or through poultry is still low at this time.
Rapid Risk Assessment: Human infection with influenza virus A(H7N9) virus - 4th update, 3 February 2015
This fourth update of the risk assessment on human infection with avian influenza A(H7N9) virus, summarises the epidemiological and virological information on the disease in China and Canada, and assesses the risk to public health in the EU/EEA and to EU/EEA citizens.
Influenza A(H7N9) virus in China - implications for public health - 7th update, 3 July 2017
Since the notification of a novel reassortant influenza A(H7N9) virus on 31 March 2013, 1 548 laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus have been reported.
Rapid risk assessment on influenza A(H7N9) China, 12 April 2013
On 31 March 2013, Chinese authorities announced the identification of a novel reassortant A(H7N9) influenza virus isolated from three unlinked cases of severe respiratory disease in eastern China. This is the first time that human infection with avian influenza virus A(H7N9) has been identified.
Since then, human cases have continued to be reported from eastern China. As of 11 April, there were 38 laboratory-confirmed cases including ten deaths reported from four bordering provinces with a concentration of cases in and around Shanghai. Cases occur sporadically, without obvious epidemiological links. There is currently no confirmed human-to-human transmission.
Rapid risk assessment: Public health risks related to communicable diseases during the hajj 2019, Saudi Arabia, 9–14 August 2019
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
- Food- and waterborne diseases
- Hepatitis A
- Hepatitis B
- Mass gathering
- Meningococcal disease
- Middle East respiratory syndrome coronavirus
- Public health threat
- Saudi Arabia
- Travellers' health
- Vaccine preventable diseases
- Vector-borne disease
Rapid risk assessment: Human infection with a novel avian influenza A(H7N9) virus, China - Third update
This updated risk assessment summarises all available information on the novel avian influenza A(H7N9) and assesses the situation as of 27 January 2014, focusing on new developments since the ECDC rapid risk assessments of 3 April 2013, 12 April 2013 and 8 May 2013.
Genetic evolution of influenza A(H7N9) virus in China - implications for public health. Sixth update, 9 March 2017
This rapid risk assessment builds on the fifth update of the ECDC rapid risk assessments on avian influenza published on 27 January 2017  and on the recent public health development dated 24 February 2017.
Rapid Risk Assessment: Outbreaks of highly pathogenic avian influenza A(H5N8) in Europe – update, 20 November 2014
On 6 November 2014, German authorities reported an outbreak of highly pathogenic avian influenza (HPAI) virus A(H5N8) at a holding with 31 000 fattening turkeys in the north-east of Germany.
Rapid risk assessment: Human fatality from highly pathogenic avian influenza A(H5N1) virus infection in Guangdong province, China
Following reports of a human fatality due to highly pathogenic avian influenza A(H5N1) virus infection in China’s Guangdong province, the European Commission requested an update to the assessment of risk of human-to-human transmission occurring. ECDC does not consider that there is any change to the previous assessments that the risk for EU/EEA countries is very low.